Core Insights - Vanda Pharmaceuticals Inc. received FDA approval for NEREUS (tradipitant), an oral neurokinin-1 receptor antagonist, aimed at preventing motion-induced vomiting in adults, leading to a 17.5% increase in share price to $8.26 in pre-market trading [1] Gainers - Aimei Health Technology Co Ltd surged 61.6% to $133.00 in pre-market trading after an 89% increase on Tuesday [4] - Anghami Inc rose 49.1% to $3.46 following the release of its six-month results [4] - Oriental Rise Holdings Ltd increased by 42.6% to $1.74 after announcing a nonbinding letter of intent to acquire a controlling stake in Hubei Daguan Tea Industry Group Co. Ltd. [4] - Northann Corp rose 39.7% to $0.27 after a 15% dip on Tuesday [4] - Inspire Veterinary Partners Inc gained 35.4% to $0.068 after an 18% increase on Tuesday [4] - iSpecimen Inc rose 29.1% to $0.38 after announcing a $5.5 million private placement [4] - Direct Digital Holdings Inc gained 28.4% to $0.077 after a 12% increase on Tuesday [4] - A SPAC III Acquisition Corp rose 25% to $34.84 [4] - LI Bang International Corporation Inc gained 24.5% to $0.66 after a 13% decline on Tuesday [4] Losers - Profusa Inc fell 14.5% to $0.10 after announcing debt restructuring and potential shareholder dilution [4] - ATIF Holdings Ltd declined 12.1% to $5.21 after filing for a mixed shelf of up to $500 million [4] - Fitell Corp fell 12.1% to $0.60 [4] - Brenmiller Energy Ltd dipped 11.8% to $0.54 after a 24% decline on Tuesday [4] - Akari Therapeutics PLC fell 11.1% to $0.24 [4] - Intercont (Cayman) Ltd declined 8.7% to $0.20 after a 4% dip on Tuesday [4] - Antelope Enterprise Holdings Ltd dipped 8.3% to $2.00 after a 92% gain on Tuesday [4] - Milestone Scientific Inc fell 8.6% to $0.25 after a 5% dip on Tuesday [4] - Jefferson Capital Inc shares dipped 7.2% to $21.08 [4] - Cybin Inc tumbled 6.6% to $8.00 after launching a $100 million at-the-market equity program [4]

Core Viewpoint - U.S. stock futures are trading lower, with several companies making headlines due to significant stock movements following recent announcements and earnings reports [1] Group 1: Company Announcements - Oriental Rise Holdings Ltd. announced a nonbinding letter of intent to acquire a controlling stake in Hubei Daguan Tea Industry Group, leading to a 47.5% increase in its share price to $1.80 in after-hours trading [1] - Vanda Pharmaceuticals Inc. received FDA approval for NEREUS (tradipitant), resulting in a 20.2% surge in its share price to $8.45 in after-hours trading [1] - One Stop Systems Inc. agreed to sell all assets of Bressner Technology GmbH for $22.4 million, while also lowering its FY2025 sales guidance due to the discontinuation of Bressner, leading to a 1.7% increase in its share price to $7.27 in after-hours trading [1] Group 2: Earnings Reports - Ellomay Capital Ltd. reported third-quarter earnings of 93 cents per share, up from 52 cents per share in the previous year, with sales increasing to $14.944 million from $13.555 million, resulting in a 16.6% rise in its share price to $26.20 [1] - FuelCell Energy Inc. filed for a common stock offering of up to $200 million, causing a 5% decline in its share price to $7.54 in after-hours trading [1]

Core Viewpoint - Vanda Pharmaceuticals Inc. has received FDA approval for NEREUS (tradipitant), leading to a significant increase in stock price by 20.20% to $8.45 in after-hours trading, indicating strong market interest in the new therapy for motion-induced vomiting in adults [1]. Clinical Efficacy - NEREUS showed efficacy in three pivotal clinical trials, with vomiting rates in treated patients ranging from 10.4% to 19.5%, compared to 37.7% to 44.3% in placebo groups, achieving risk reductions of over 50% to 70% [2]. - The Motion Syros trial involved 365 patients, while the Motion Serifos study included 316 patients, both demonstrating statistically significant results (p < 0.0001 and p ≤ 0.0014 respectively) [2]. Adverse Reactions - Common adverse reactions reported included somnolence in 6% to 12% of patients and fatigue in 6% to 8% [3]. Market Potential - Approximately 25% to 30% of U.S. adults, estimated at 65 million to 78 million people, experience motion sickness, with 5% to 15% suffering from severe, recurrent symptoms, highlighting a substantial market opportunity for NEREUS [4]. Pipeline Development - Vanda is also advancing tradipitant for other indications, including gastroparesis and nausea/vomiting prevention related to GLP-1 receptor agonists, indicating a broader therapeutic potential [5]. Trading Metrics - Vanda Pharmaceuticals has a market capitalization of $415.45 million, with a 52-week high of $7.47 and a low of $3.81. The stock has gained 47.07% over the past 12 months, reflecting a strong long-term trend [6]. - The stock is currently trading at 88% of its 52-week range, suggesting bullish sentiment, although it is approaching overbought levels [6]. Price Action - On the previous trading day, the stock closed at $7.03, down 2.36%, but maintains strong momentum in the 90th percentile, indicating a positive price trend across all time frames [7].